

## **Allergy Therapeutics<sup>PLC</sup>**

### **Allergy Therapeutics plc**

("Allergy Therapeutics" or the "Company" or "Group")

#### **Allergy Therapeutics announces the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director**

- *Newly created Chief Strategy Officer role will drive long-term international growth strategy as Group advances next-generation pipeline and explores opportunities to deliver on global ambitions*
- *Appointments strengthen Board, each bringing decades of expertise in their respective fields to support Company's ambition to become a global leader in allergy treatments*

**30 January 2026** - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the appointment of Helge Weiner-Trapness as Chief Strategy Officer. He also joins the Group's Board as an Executive Director.

Helge has more than 30 years of experience across leading global investment banks in the US and Asia. He most recently served as Vice Chairman, Global Banking at HSBC Holdings plc (LSE: HSBA; HKG: 0005), one of the world's largest financial organisations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. He was a Founding Partner of Hong Kong-based Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. Earlier, he held senior roles at Barclays Bank, Asia Pacific Land, J.P. Morgan Securities and Goldman Sachs.

In his newly created role as Chief Strategy Officer, Helge will drive Allergy Therapeutics' long-term growth strategy, including corporate development, partnership strategy and portfolio prioritisation as Allergy Therapeutics advances its next-generation pipeline and explores opportunities to deliver on its global ambitions.

**Helge Weiner-Trapness, Chief Strategy Officer and Executive Director, said:** *"Allergy Therapeutics has established a leading position in its core markets, with a significant portfolio and an innovative pipeline that present a strong platform for future growth. I am looking forward to working with the Board and management team to drive the Company's long-term strategy and international development, prioritising opportunities and executing a global strategy in a disciplined and sustainable way."*

Allergy Therapeutics also announces that Lawrence Allen Wang will join the Company's Board as an independent Non-Executive Director. Lawrence has more than 20 years' experience across healthcare and investment roles. He currently serves as Chief Financial Officer of Adicon Clinical Laboratories, Inc. (HKG: 9860), one of China's leading independent clinical laboratory service providers, where he played a key role in the company's financing and its listing on the Hong Kong Stock Exchange. Prior to Adicon, Lawrence held roles in private equity, asset management and investment banking groups, including positions at Vivo Capital, Primavera Capital, Macquarie Group and Goldman Sachs (Asia).

**Lawrence Allen Wang, Independent Non-Executive Director, said:** *"Allergy Therapeutics has built a strong clinical and commercial platform, and I look forward to supporting the Board as the Company continues to develop its international strategy to become a global leader in allergy treatments."*

**Peter Jensen, Chairman of Allergy Therapeutics, said:** *"On behalf of the Board, I am pleased to welcome Helge*

Robert Jensen, Chairman of Allergy Therapeutics, said: "On behalf of the Board, I am pleased to welcome Naye and Larry to Allergy Therapeutics. Both bring deep investment and healthcare expertise that will be instrumental as the Company pursues its long-term growth ambitions, including evaluating a potential dual listing on the Hong Kong Stock Exchange. These appointments reflect our continued focus on building a Board with the experience and perspective required to support the Company's next phase of international development."

**Additional information in respect of the AIM Rules:**

**INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES ("AIM RULES")**

<b>Full name:</b>	<b>Lawrence Allen Wang</b>
<b>Age:</b>	<b>49</b>
<b>Shares held in the Company:</b>	<b>None</b>
<b>Current directorships:</b>	<b>Adicon International Limited</b> <b>Manson Grand International Limited</b> <b>Hong Kong Yuan De Weike International Trade Co. Limited</b> <b>Miramar Lifesciences Limited</b>
<b>Historic directorships and partnerships in previous 5 years:</b>	<b>None</b>

<b>Full name:</b>	<b>Erik Helge Weiner-Trapness</b>
<b>Age:</b>	<b>62</b>
<b>Shares held in the Company:</b>	<b>None</b>
<b>Current directorships:</b>	<b>Sterling and Francine Clark Art Institute</b>
<b>Historic directorships and partnerships in previous 5 years:</b>	<b>Quintus Partners LLC</b> <b>Quintus Partners Limited</b> <b>International Financing Facility for Immunization ("IFFIm")</b> <b>Surgical Specialties Corporation Limited</b>

There is no further information to be disclosed in relation to the appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.

**For further information, please contact:**

**Allergy Therapeutics**

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

**Cavendish Capital Markets Limited (Nominated Adviser and Broker)**

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

**ICR Healthcare**

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

[allergytherapeutics@icrhealthcare.com](mailto:allergytherapeutics@icrhealthcare.com)

**Notes for editors:**

**About Allergy Therapeutics**

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries and branches in nine major European countries and via distribution agreements in an additional four countries. For more information, please see [www.allergytherapeutics.com](http://www.allergytherapeutics.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAVBLBXQFLLBBL